Literature DB >> 26542697

Phone and Video-Based Modalities of Central Blinded Adjudication of Modified Rankin Scores in an Endovascular Stroke Trial.

Elena López-Cancio1, Mercè Salvat2, Neus Cerdà2, Marta Jiménez2, Javier Codas2, Laura Llull2, Sandra Boned2, Luis M Cano2, Blanca Lara2, Carlos Molina2, Erik Cobo2, Antoni Dávalos2, Tudor G Jovin2, Joaquín Serena2.   

Abstract

BACKGROUND AND
PURPOSE: The standard outcome measure in stroke research is modified Rankin scale (mRS) evaluated by local blinded investigators. We aimed to assess feasibility and reliability of 2 central adjudication methods of mRS in the setting of a randomized endovascular stroke trial.
METHODS: This is a secondary analysis derived from the Randomized Trial of Revascularization With Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset (REVASCAT) trial cohort. Primary outcome was distribution of mRS at 90 days. Local evaluation was done by certified investigators masked to treatment assignment using structured face-to-face interviews. In addition, central assessment was performed by 2 independent raters via structured phone interview (n=120) and via video recordings of the face-to-face interviews with local investigators (n=106). Interrater agreement was evaluated using kappa and discordance statistics. Sensitivity analyses for the primary end point using different adjudication approaches were performed. Correlation between mRS obtained with each modality and 24-hour follow-up infarct volumes was studied.
RESULTS: Using local evaluation as the reference, higher agreement rates were noted with central video than with central phone evaluations (kw 0.92 [0.88-0.96] versus 0.77 [0.72-0.83]). Discrepancies in mRS scoring between local and central raters (phone- and video-based) were similar in both treatment allocation arms. Sensitivity analyses showed benefit of endovascular treatment irrespective of adjudication method, but higher odds ratios were observed with local evaluations. Final infarct volume was similarly correlated with mRS across all 3 evaluation modalities.
CONCLUSIONS: Central adjudication of mRS is feasible, reducing interrater variability and avoiding potential problems related to lack of blinding. Our findings may have implications in the planning of future randomized acute stroke trials, especially in those including nonpharmacological interventions. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01692379.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  Rankin; central adjudication; endovascular; odds ratio; stroke trial

Mesh:

Year:  2015        PMID: 26542697     DOI: 10.1161/STROKEAHA.115.010909

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  4 in total

1.  Effect of Routine Low-Dose Oxygen Supplementation on Death and Disability in Adults With Acute Stroke: The Stroke Oxygen Study Randomized Clinical Trial.

Authors:  Christine Roffe; Tracy Nevatte; Julius Sim; Jon Bishop; Natalie Ives; Phillip Ferdinand; Richard Gray
Journal:  JAMA       Date:  2017-09-26       Impact factor: 56.272

2.  Simvastatin inhibits the apoptosis of hippocampal cells in a mouse model of Alzheimer's disease.

Authors:  Xiaoqin Hu; Chengwei Song; Ming Fang; Chengyan Li
Journal:  Exp Ther Med       Date:  2017-12-12       Impact factor: 2.447

3.  Outcome assessment by central adjudicators in randomised stroke trials: Simulation of differential and non-differential misclassification.

Authors:  Peter J Godolphin; Philip M Bath; Christopher Partlett; Eivind Berge; Martin M Brown; Misha Eliasziw; Per Morten Sandset; Joaquín Serena; Alan A Montgomery
Journal:  Eur Stroke J       Date:  2020-02-26

4.  Added Value of a Blinded Outcome Adjudication Committee in an Open-Label Randomized Stroke Trial.

Authors:  Nadinda A M van der Ende; Bob Roozenbeek; Olvert A Berkhemer; Peter J Koudstaal; Jelis Boiten; Ewoud J van Dijk; Yvo B W E M Roos; Robert J van Oostenbrugge; Charles B L M Majoie; Wim van Zwam; Hester F Lingsma; Aad van der Lugt; Diederik W J Dippel
Journal:  Stroke       Date:  2021-10-05       Impact factor: 7.914

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.